| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Enterobacteriaceae | 18 | 2020 | 395 | 3.89 | Why? |
| Bacteremia | 25 | 2020 | 1372 | 3.61 | Why? |
| Enterobacteriaceae Infections | 18 | 2019 | 529 | 3.49 | Why? |
| Escherichia coli Infections | 7 | 2018 | 348 | 2.15 | Why? |
| beta-Lactamases | 15 | 2019 | 759 | 2.14 | Why? |
| Anti-Bacterial Agents | 38 | 2021 | 10083 | 1.86 | Why? |
| Gram-Negative Bacteria | 6 | 2019 | 473 | 1.85 | Why? |
| Drug Resistance, Multiple, Bacterial | 15 | 2019 | 1115 | 1.70 | Why? |
| Escherichia coli | 13 | 2019 | 1547 | 1.69 | Why? |
| Urinary Tract Infections | 6 | 2019 | 534 | 1.68 | Why? |
| Drug Resistance, Bacterial | 15 | 2021 | 1414 | 1.52 | Why? |
| beta-Lactamase Inhibitors | 7 | 2019 | 104 | 1.46 | Why? |
| Gram-Negative Bacterial Infections | 6 | 2019 | 398 | 1.42 | Why? |
| Rectum | 4 | 2018 | 495 | 1.32 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 2 | 2018 | 214 | 1.15 | Why? |
| Fosfomycin | 4 | 2018 | 48 | 1.07 | Why? |
| Cross Infection | 16 | 2019 | 8675 | 0.91 | Why? |
| Treatment Failure | 2 | 2018 | 2106 | 0.90 | Why? |
| Anti-Infective Agents | 5 | 2019 | 1766 | 0.86 | Why? |
| beta-Lactam Resistance | 3 | 2017 | 150 | 0.77 | Why? |
| Pneumonia, Staphylococcal | 1 | 2017 | 38 | 0.70 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 6 | 2019 | 711 | 0.69 | Why? |
| Sepsis | 9 | 2018 | 3517 | 0.67 | Why? |
| Klebsiella pneumoniae | 8 | 2019 | 658 | 0.66 | Why? |
| Antimicrobial Stewardship | 4 | 2019 | 931 | 0.64 | Why? |
| Blood | 1 | 2017 | 274 | 0.63 | Why? |
| Microbial Sensitivity Tests | 16 | 2019 | 2886 | 0.61 | Why? |
| Vagina | 1 | 2018 | 327 | 0.60 | Why? |
| Staphylococcus aureus | 2 | 2019 | 844 | 0.58 | Why? |
| Microbiological Techniques | 1 | 2017 | 232 | 0.57 | Why? |
| Pseudomonas Infections | 2 | 2019 | 425 | 0.57 | Why? |
| Prosthesis-Related Infections | 2 | 2018 | 302 | 0.56 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.55 | Why? |
| Staphylococcal Infections | 4 | 2019 | 1099 | 0.55 | Why? |
| Carbapenems | 6 | 2019 | 343 | 0.52 | Why? |
| beta-Lactams | 5 | 2018 | 210 | 0.50 | Why? |
| Arthroplasty, Replacement, Knee | 1 | 2018 | 363 | 0.48 | Why? |
| Bacterial Proteins | 9 | 2019 | 1318 | 0.48 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2018 | 403 | 0.48 | Why? |
| Acinetobacter baumannii | 5 | 2019 | 378 | 0.47 | Why? |
| Pseudomonas aeruginosa | 5 | 2019 | 652 | 0.45 | Why? |
| Bacteria | 4 | 2017 | 1897 | 0.43 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2018 | 861 | 0.40 | Why? |
| Klebsiella Infections | 4 | 2018 | 466 | 0.38 | Why? |
| Carrier State | 2 | 2018 | 2100 | 0.34 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.33 | Why? |
| Intraabdominal Infections | 2 | 2017 | 90 | 0.32 | Why? |
| Immunocompromised Host | 2 | 2019 | 5150 | 0.29 | Why? |
| Inappropriate Prescribing | 2 | 2019 | 284 | 0.29 | Why? |
| Parents | 1 | 2019 | 2758 | 0.29 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.28 | Why? |
| Bacterial Infections | 4 | 2019 | 2229 | 0.27 | Why? |
| Risk Factors | 17 | 2021 | 71621 | 0.27 | Why? |
| Stenotrophomonas maltophilia | 2 | 2019 | 63 | 0.26 | Why? |
| Quality Indicators, Health Care | 2 | 2019 | 580 | 0.26 | Why? |
| Neutropenia | 2 | 2017 | 388 | 0.25 | Why? |
| Spain | 13 | 2021 | 15545 | 0.25 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 2 | 2017 | 72 | 0.25 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.25 | Why? |
| ROC Curve | 4 | 2021 | 6024 | 0.25 | Why? |
| Humans | 77 | 2021 | 930598 | 0.24 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.24 | Why? |
| Penicillanic Acid | 2 | 2015 | 58 | 0.23 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.23 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.23 | Why? |
| Community-Acquired Infections | 3 | 2017 | 2328 | 0.22 | Why? |
| Europe | 11 | 2019 | 12702 | 0.22 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.22 | Why? |
| Aged | 32 | 2021 | 215776 | 0.21 | Why? |
| Minocycline | 2 | 2017 | 101 | 0.20 | Why? |
| Pneumonia, Bacterial | 2 | 2017 | 843 | 0.20 | Why? |
| Prospective Studies | 13 | 2020 | 43301 | 0.19 | Why? |
| Uropathogenic Escherichia coli | 1 | 2018 | 10 | 0.19 | Why? |
| Male | 40 | 2021 | 367725 | 0.19 | Why? |
| Communicable Diseases | 3 | 2018 | 2148 | 0.19 | Why? |
| Knee Prosthesis | 1 | 2018 | 40 | 0.18 | Why? |
| Female | 40 | 2021 | 380317 | 0.18 | Why? |
| Middle Aged | 33 | 2021 | 270681 | 0.18 | Why? |
| Shock, Septic | 2 | 2019 | 1313 | 0.18 | Why? |
| Hip Prosthesis | 1 | 2018 | 54 | 0.18 | Why? |
| Quorum Sensing | 1 | 2017 | 26 | 0.17 | Why? |
| Societies, Scientific | 2 | 2018 | 414 | 0.17 | Why? |
| Cohort Studies | 9 | 2021 | 36005 | 0.17 | Why? |
| Educational Technology | 1 | 2018 | 101 | 0.17 | Why? |
| Thienamycins | 1 | 2017 | 72 | 0.17 | Why? |
| Bacterial Outer Membrane Proteins | 1 | 2017 | 60 | 0.17 | Why? |
| Aminoglycosides | 1 | 2017 | 94 | 0.17 | Why? |
| Medical Laboratory Science | 1 | 2018 | 122 | 0.17 | Why? |
| Health Impact Assessment | 1 | 2019 | 181 | 0.17 | Why? |
| Quinolones | 1 | 2018 | 167 | 0.16 | Why? |
| Preceptorship | 1 | 2018 | 115 | 0.16 | Why? |
| Ceftriaxone | 1 | 2019 | 365 | 0.16 | Why? |
| Perioperative Period | 1 | 2018 | 276 | 0.16 | Why? |
| Bile Acids and Salts | 1 | 2017 | 91 | 0.16 | Why? |
| Enterocolitis, Pseudomembranous | 1 | 2017 | 93 | 0.16 | Why? |
| Livestock | 1 | 2017 | 184 | 0.16 | Why? |
| Microbiology | 1 | 2018 | 134 | 0.16 | Why? |
| Gram-Positive Bacteria | 1 | 2017 | 230 | 0.16 | Why? |
| Aged, 80 and over | 17 | 2021 | 88759 | 0.16 | Why? |
| Escherichia coli Proteins | 1 | 2017 | 168 | 0.15 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.15 | Why? |
| Prevalence | 7 | 2021 | 25773 | 0.15 | Why? |
| Case-Control Studies | 4 | 2018 | 17671 | 0.15 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.15 | Why? |
| Monte Carlo Method | 1 | 2018 | 577 | 0.15 | Why? |
| Colistin | 1 | 2017 | 217 | 0.14 | Why? |
| Retrospective Studies | 15 | 2021 | 105322 | 0.14 | Why? |
| Publications | 1 | 2020 | 463 | 0.14 | Why? |
| Meat | 1 | 2017 | 380 | 0.14 | Why? |
| Hospitals | 5 | 2021 | 11793 | 0.14 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.13 | Why? |
| Fungi | 1 | 2017 | 471 | 0.13 | Why? |
| Survival Analysis | 5 | 2019 | 7592 | 0.13 | Why? |
| Drug Therapy, Combination | 4 | 2020 | 7268 | 0.13 | Why? |
| Evidence-Based Practice | 1 | 2019 | 693 | 0.12 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.12 | Why? |
| Prognosis | 8 | 2021 | 32490 | 0.12 | Why? |
| Piperacillin | 2 | 2015 | 63 | 0.12 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.12 | Why? |
| Practice Guidelines as Topic | 2 | 2018 | 15421 | 0.12 | Why? |
| Organ Dysfunction Scores | 1 | 2018 | 1475 | 0.11 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.11 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.11 | Why? |
| Adult | 19 | 2021 | 244371 | 0.11 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.11 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.11 | Why? |
| Search Engine | 1 | 2018 | 628 | 0.11 | Why? |
| Odds Ratio | 2 | 2019 | 5861 | 0.10 | Why? |
| Infection Control | 3 | 2018 | 23131 | 0.10 | Why? |
| Kinetics | 1 | 2018 | 3238 | 0.10 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.10 | Why? |
| Virulence | 1 | 2017 | 2172 | 0.10 | Why? |
| Tertiary Care Centers | 2 | 2018 | 8248 | 0.10 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.10 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.09 | Why? |
| Population Surveillance | 4 | 2017 | 4967 | 0.09 | Why? |
| Family Characteristics | 1 | 2018 | 2551 | 0.09 | Why? |
| Feces | 2 | 2018 | 4235 | 0.09 | Why? |
| Gene Expression Regulation, Bacterial | 2 | 2017 | 143 | 0.08 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Patient Care | 1 | 2017 | 1664 | 0.08 | Why? |
| Hospitals, Community | 1 | 2010 | 475 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Fluoroquinolones | 1 | 2006 | 235 | 0.07 | Why? |
| Liver Diseases | 1 | 2021 | 2698 | 0.07 | Why? |
| Incidence | 3 | 2019 | 25622 | 0.07 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.07 | Why? |
| Education, Medical, Undergraduate | 1 | 2018 | 1392 | 0.07 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.07 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.07 | Why? |
| Cephalosporins | 1 | 2006 | 250 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.07 | Why? |
| Virulence Factors | 2 | 2017 | 338 | 0.07 | Why? |
| Endocarditis, Bacterial | 1 | 2009 | 344 | 0.07 | Why? |
| Disease Outbreaks | 3 | 2018 | 27595 | 0.07 | Why? |
| Disease Management | 2 | 2019 | 6841 | 0.06 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.06 | Why? |
| International Cooperation | 1 | 2017 | 3436 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.06 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.06 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.06 | Why? |
| Patient Discharge | 1 | 2018 | 5696 | 0.06 | Why? |
| Protein Isoforms | 1 | 2002 | 347 | 0.05 | Why? |
| Leptin | 1 | 2002 | 141 | 0.05 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.05 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.05 | Why? |
| Cross-Sectional Studies | 5 | 2018 | 53120 | 0.05 | Why? |
| Vancomycin | 2 | 2017 | 328 | 0.05 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Propensity Score | 2 | 2019 | 2690 | 0.05 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.05 | Why? |
| Carrier Proteins | 1 | 2002 | 513 | 0.05 | Why? |
| Organization and Administration | 1 | 2018 | 93 | 0.05 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.05 | Why? |
| Students, Medical | 1 | 2018 | 4032 | 0.05 | Why? |
| Retrognathia | 1 | 2017 | 17 | 0.04 | Why? |
| Genes, MDR | 1 | 2017 | 9 | 0.04 | Why? |
| Type VI Secretion Systems | 1 | 2017 | 9 | 0.04 | Why? |
| Receptors, Cell Surface | 1 | 2002 | 586 | 0.04 | Why? |
| Time Factors | 2 | 2019 | 31397 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Agar | 1 | 2017 | 15 | 0.04 | Why? |
| Klebsiella | 1 | 2017 | 35 | 0.04 | Why? |
| Pseudomonas | 1 | 2017 | 65 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.04 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.04 | Why? |
| Internship and Residency | 1 | 2018 | 4987 | 0.04 | Why? |
| Drug Administration Routes | 1 | 2017 | 106 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2020 | 801 | 0.04 | Why? |
| Drug Tolerance | 1 | 2017 | 100 | 0.04 | Why? |
| Clinical Medicine | 1 | 2018 | 93 | 0.04 | Why? |
| Food Microbiology | 1 | 2017 | 114 | 0.04 | Why? |
| Mortality | 3 | 2019 | 7132 | 0.04 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.04 | Why? |
| Social Media | 1 | 2018 | 5798 | 0.04 | Why? |
| Genes, Bacterial | 1 | 2017 | 207 | 0.04 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.04 | Why? |
| Ciprofloxacin | 1 | 2017 | 130 | 0.04 | Why? |
| Vancomycin-Resistant Enterococci | 1 | 2017 | 104 | 0.04 | Why? |
| Ceftazidime | 1 | 2017 | 134 | 0.04 | Why? |
| Infant | 1 | 2018 | 30274 | 0.04 | Why? |
| Blood Culture | 1 | 2017 | 308 | 0.04 | Why? |
| Adolescent | 8 | 2020 | 86841 | 0.04 | Why? |
| Editorial Policies | 1 | 2020 | 408 | 0.04 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.04 | Why? |
| Glomerular Filtration Rate | 1 | 2021 | 1262 | 0.03 | Why? |
| Cause of Death | 2 | 2020 | 4823 | 0.03 | Why? |
| Culture Media | 1 | 2017 | 366 | 0.03 | Why? |
| Public Health | 2 | 2017 | 16359 | 0.03 | Why? |
| Biofilms | 1 | 2017 | 304 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2018 | 14232 | 0.03 | Why? |
| Quality Assurance, Health Care | 1 | 2018 | 596 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2017 | 835 | 0.03 | Why? |
| Research Support as Topic | 1 | 2017 | 327 | 0.03 | Why? |
| Critical Illness | 1 | 2016 | 17281 | 0.03 | Why? |
| Bacterial Typing Techniques | 1 | 2014 | 273 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2002 | 2742 | 0.03 | Why? |
| Chlorhexidine | 1 | 2014 | 176 | 0.03 | Why? |
| Superinfection | 1 | 2017 | 459 | 0.03 | Why? |
| Intensive Care Units | 1 | 2017 | 29594 | 0.03 | Why? |
| Evidence-Based Medicine | 2 | 2017 | 3228 | 0.03 | Why? |
| Research Design | 2 | 2017 | 5830 | 0.03 | Why? |
| Sentinel Surveillance | 1 | 2017 | 1093 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2002 | 4020 | 0.02 | Why? |
| Methicillin Resistance | 1 | 2009 | 77 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.02 | Why? |
| Netherlands | 1 | 2018 | 3533 | 0.02 | Why? |
| Gastrointestinal Tract | 1 | 2017 | 1113 | 0.02 | Why? |
| Hospitals, University | 2 | 2015 | 4173 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.02 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Oxygen | 1 | 2021 | 3715 | 0.02 | Why? |
| Anti-Infective Agents, Local | 1 | 2014 | 520 | 0.02 | Why? |
| Periodicals as Topic | 1 | 2020 | 1492 | 0.02 | Why? |
| Device Removal | 1 | 2009 | 221 | 0.02 | Why? |
| Catheterization | 1 | 2009 | 264 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2018 | 43792 | 0.02 | Why? |
| Long-Term Care | 1 | 2018 | 2047 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Self Report | 1 | 2018 | 3802 | 0.02 | Why? |
| Databases, Factual | 1 | 2021 | 6248 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Health Personnel | 1 | 2015 | 29646 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2002 | 6670 | 0.02 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2017 | 3493 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.02 | Why? |
| Catheterization, Central Venous | 1 | 2009 | 458 | 0.02 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.02 | Why? |
| Animals | 3 | 2017 | 78931 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Global Health | 2 | 2017 | 13911 | 0.02 | Why? |
| Hematologic Neoplasms | 1 | 2017 | 2105 | 0.02 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.02 | Why? |
| Receptors, Leptin | 1 | 2002 | 12 | 0.02 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.02 | Why? |
| Hand Hygiene | 1 | 2014 | 1493 | 0.02 | Why? |
| Phytohemagglutinins | 1 | 2002 | 15 | 0.02 | Why? |
| Concanavalin A | 1 | 2002 | 19 | 0.02 | Why? |
| Heart Valve Prosthesis | 1 | 2009 | 533 | 0.02 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.02 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2009 | 552 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Length of Stay | 1 | 2019 | 11042 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.01 | Why? |
| Models, Theoretical | 1 | 2019 | 6659 | 0.01 | Why? |
| Equipment Contamination | 1 | 2009 | 1308 | 0.01 | Why? |
| Early Diagnosis | 1 | 2009 | 2443 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Protein Processing, Post-Translational | 1 | 2002 | 634 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Phosphorylation | 1 | 2002 | 1060 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| HIV Infections | 1 | 2002 | 11620 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Recombinant Proteins | 1 | 2002 | 3786 | 0.01 | Why? |
| Cells, Cultured | 1 | 2002 | 5835 | 0.01 | Why? |
| Hepatitis C | 1 | 2002 | 1514 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |
| RNA, Messenger | 1 | 2002 | 5131 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.00 | Why? |
| Signal Transduction | 1 | 2002 | 7207 | 0.00 | Why? |
| Child | 1 | 2002 | 70012 | 0.00 | Why? |